© IATDMCT2025.org
created by Aptly Web Design
Lunch workshops
The IATDMCT 2025 Congress features a range of dynamic sponsored lunch workshops, open to all delegates at no additional cost. Simply select your preferred sessions during the registration process.
If you have already registered and wish to attend a lunch workshop, please contact the congress organisers at iatdmct2025@expertevents.com.au.
Further workshops will be announced by email to IATDMCT members and registered delegates. Workshops will be limited in size and filled by a first come, first served basis.
Oncocyte Workshop
Wednesday 24 September 2025
Donor-derived cell-free DNA for personalized immunosuppression in transplantation
Presented by:
Michael Oellerich
Department of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany
Donor-derived cell-free DNA (dd-cfDNA) is an effective diagnostic tool for serial surveillance of allograft health. Absolute quantification of dd-cfDNA is superior to fractional determination as it is not affected by changes of total cfDNA. Recently a new dd-cfDNA test kit for quick in-house determinations (GraftAssureTM) has been developed based on ddPCR with preselected SNPs, which enables measurements of fractional abundance (%) and absolute concentration (cp/ml). Significantly elevated absolute dd-cfDNA levels (cp/ml) were found in patients with acute or chronic antibody mediated rejection (ABMR), DSA negative patients with microvascular inflammation or BK-virus nephropathy. Low-grade T-cell-mediated rejection (TCMR) (IA) without vascular injury was not well detected in plasma in contrast to high-grade TCMR. The diagnostic performance of plasma dd-cfDNA for rejection detection is in general very good for kidney, heart, lung and liver transplant recipients (range of mean values: AUC-ROC 0.79 – 0.95, sensitivity 66 – 90 %, specificity 76 – 88 %, PPV 33 – 63 %, NPV 89 – 100 %). ABMR remains a major therapeutic challenge and causes about 20 – 30 % of allograft failures. Dd-cfDNA is useful for early ABMR detection, in particular in DSA+ patients. New treatment options using CD38-targeting monoclonal antibodies (CD38 mAB) are currently evaluated and dd-cfDNA has been used successfully as a companion biomarker in patients with chronic ABMR. In a recent randomized clinical trial longitudinal dd-cfDNA monitoring was performed for ABMR detection in kidney transplant recipients. The time from study inclusion to ABMR diagnosis was on average 2.8 months in the intervention group with dd-cfDNA guided biopsy and 14.5 months in the control group with clinician guided biopsy. In contrast to ABMR there was no significant elevation of dd-cfDNA in patients with IgA nephropathy (IgAN). Based on currently available evidence Medicare provides coverage for dd-cfDNA routine testing in the US. Dd-cfDNA facilitates personalized immunosuppression and cost-effective transplant recipient surveillance with the potential to reduce premature graft loss.
Shimadzu Workshop
Wednesday 24 September 2025
Quantitative and simultaneous plasma drug analysis with LC-MS/MS for therapeutic drug monitoring
Presented by:
Masamitsu Maekawa
Nariyasu Mano, Department of Pharmaceutical Sciences, Tohoku University Hospital
Therapeutic drug monitoring (TDM) is an important approach in personalized medicine.
Recently, liquid chromatography/tandem mass spectrometry (LC-MS/MS) methods have come into clinical use including TDM.
However, the introduction of TDM with LC-MS/MS has presented several challenges.
One is method development in each laboratory.
Another issue is that LC-MS/MS requires pretreatment processing techniques and time.
Furthermore, preparation of optimal MS/MS instrument in your facility is problematic.
Therefore, in this seminar, we would like to show the basics of drug plasma LC-MS/MS analysis method development, automation pretreatment processing for LC/MS/MS, and the possibility of using a time-of-flight MS/MS equipment for TDM.
For plasma drug analysis, triple quadrupole MS/MS or quadrupole-time-of-flight hybrid MS/MS were used.
After the addition of internal standard, samples were pretreated with acetonitrile for protein precipitation with a fully automated sample preparation module.
The developed method, which was verified by method validation, was used to analyze drug plasma concentrations of clinical drugs.
For antipsychotics, anticancer drugs, immunosuppressants, and antifungal drugs, the simultaneous drug plasma concentration analysis methods were developed successfully by LC-MS/MS and applied to clinical practice and research for TDM.
There was no difference in plasma drug concentrations between automated pretreatment processing and human procedure. QTOF MS/MS might be also applied for quantitative plasma drug analysis.
LC-MS/MS is useful for drug analysis for clinical TDM practice, and it is evolving to be more easily implemented in clinical TDM.
